LifeCanvas Technologies is a tissue clearing and light-sheet imaging company in Cambridge, Massachusetts, founded by Kwanghun Chung of the Massachusetts Institute of Technology.[S2][S3] It is not a general nonclinical contract research organization, and reading it as one would lead a sponsor to the wrong scope. The company sells instruments, reagents and analysis software for making whole organs optically transparent and imaging them intact, and it also runs those workflows as a service on tissue that clients send in.[S1][S4][S9] The service pages are explicit about the handoff: the client ships fixed samples.[S4][S5] For the services described on the reviewed pages, clients ship fixed samples; confirm separately where dosing, in-life observation and necropsy will be performed. LifeCanvas describes three-dimensional whole-organ imaging and analysis of client-supplied fixed tissue.
Services relevant to US drug developers
What is and is not in scope
The contract services are whole-organ tissue clearing, immunolabeling, imaging and analysis, performed on paraformaldehyde-fixed material supplied by the client.[S4][S8] No service line was found for in-life efficacy dosing, GLP toxicology, safety pharmacology, drug metabolism and pharmacokinetics, bioanalysis, or standalone histopathology reporting, and no statement was found describing animal housing at the company own site.[S1][S4] A sponsor would therefore place a study with an in vivo laboratory and send the fixed tissue here, or run the in-life phase internally. Where a program already has a source of tissue, sponsors using this workflow should confirm sample transfer requirements, responsibilities and timelines with both providers.
Biodistribution and activity mapping
Two of the named services map directly onto questions that come up in nonclinical development. The first is three-dimensional mapping of adeno-associated virus vector biodistribution across whole organs, delivered as heat maps and quantitative plots through a web portal.[S5] The company offers three-dimensional AAV vector biodistribution mapping across whole organs, delivering heat maps and quantitative plots through a web portal. The second is brain-wide mapping of c-FOS positive cells, registered to a reference brain atlas, used to describe where neural activity changed.[S6] A third service quantifies amyloid beta plaque and alpha-synuclein aggregate burden in intact brains from neurodegenerative disease models.[S7] These are descriptive readouts of what happened in the tissue supplied; they do not by themselves establish efficacy, and the company does not present them as doing so.
Instruments and reagents sold to run in house
The same workflows are sold as products for laboratories that prefer to run them internally. SHIELD is a preservation chemistry that the company states protects endogenous fluorescence, protein antigenicity, nucleic acids and tissue architecture before clearing.[S9] SmartBatch+ is an instrument that performs active clearing and immunolabeling, with stated throughput of up to twelve whole mouse brains in about a day, or two whole rat brains in three to four days.[S9] SmartSPIM is a light-sheet microscope stated to image a mouse brain hemisphere in under thirty minutes at a voxel size of roughly 1.8 by 1.8 by 4 micrometers.[S10] DALISPIM, announced in October 2025, is an open-top inverted design that images samples directly in multiwell plates, dishes and organ-on-a-chip devices.[S12] MegaSPIM is listed in the same product family, but the page reviewed did not carry specifications distinct from the family description, so it is named here without detail.[S9] SmartAnalytics provides automated registration to mouse and rat brain atlases with pretrained models for several markers.[S11]
Quality, compliance, and animal welfare (as stated by the company)
No GLP claim was found on the pages reviewed, and no reference to AAALAC accreditation, USDA registration, an OLAW Animal Welfare Assurance, or an Institutional Animal Care and Use Committee was found on the pages reviewed.[S1][S2][S4] That is an absence in those pages, not a finding about the status of the company: the accreditations above relate to the care and use of live animals, and the company describes receiving tissue that has already been fixed.[S4] AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] A sponsor intending to use imaging data in a regulatory submission should establish where the study record begins, since the GLP status of a study is determined for the study as a whole under the applicable regulation, including work placed with a subcontractor.[R2] No ISO, clinical laboratory or other quality system certification was found on the site either.
Company facts
Name
LifeCanvas Technologies; no legal entity suffix is given on the site[S1]
Headquarters
1035 Cambridge Street, Suite 16C, Cambridge, MA 02141, United States[S3]
FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies Replicate unknown pathological models and Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
SMC Laboratories, Inc. has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc. (Labcorp Drug Development)
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
Japanese
